Research
Nattokinase
9 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Systematic review and meta-analysis of six RCTs with 546 participants evaluating nattokinase supplementation on cardiovascular risk factors. Nattokinase significantly reduced systolic and diastolic blood pressure but had mixed effects on cholesterol levels and a slight increase in blood glucose. No significant correlation with triglycerides was found.
Nattokinase atherothrombotic prevention study: A randomized controlled trial.
This double-blinded RCT studied the effect of nattokinase supplementation on subclinical atherosclerosis progression and atherothrombotic biomarkers in 265 individuals. After a median of 3 years, nattokinase showed no significant effect on carotid artery intima-media thickness, carotid arterial stiffness, blood pressure, or any laboratory measures compared to placebo.
Nattokinase supplementation for cognitive enhancement in asymptomatic intracranial/carotid stenosis: A randomized controlled trial.
RCT evaluating the effects of 6-month nattokinase supplementation on cognitive function in 120 patients with asymptomatic intracranial/carotid artery stenosis. No significant improvement in global cognition was found, but there was a significant enhancement in visuospatial function in the nattokinase group.
Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases.
RCT evaluating the efficacy and safety of nattokinase (100 mg/day) in 153 patients with vascular diseases undergoing vascular surgery. Nattokinase improved clinical symptoms without adverse drug reactions or interactions, suggesting it is an efficient and safe treatment for preventing and treating vascular diseases.
The effects of nattokinase supplementation on collagen-epinephrine closure time, prothrombin time and activated partial thromboplastin time in nondiabetic and hypercholesterolemic subjects.
RCT investigating the effects of nattokinase supplementation on hemostatic factors in hypercholesterolemic subjects. The nattokinase group showed significant increases in collagen-epinephrine closure time, prothrombin time, and activated partial thromboplastin time compared to placebo after 8 weeks.
Effects of nattokinase on blood pressure: a randomized, controlled trial.
RCT examining the effects of nattokinase supplementation on blood pressure in 86 subjects with pre-hypertension or stage 1 hypertension. Nattokinase reduced systolic and diastolic blood pressure compared to placebo after 8 weeks, suggesting potential benefits for hypertension management.
A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles.
A double-blind, placebo-controlled cross-over study in 12 healthy young males assessed the effects of a single-dose of 2,000 FU nattokinase on coagulation/fibrinolysis parameters. Nattokinase administration significantly elevated D-dimer concentrations and fibrin/fibrinogen degradation products, decreased Factor VIII activity, increased blood antithrombin concentration, and prolonged activated partial thromboplastin time, all within normal ranges.
Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia.
RCT evaluating the lipid-lowering effect of nattokinase and nattokinase combined with red yeast rice in 47 patients with hyperlipidemia. The combined formula significantly improved blood lipids, including triglycerides, total cholesterol, LDL-C, and HDL-C, compared to placebo, while nattokinase alone showed no effect until month six.
Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects.
An open-label, self-controlled clinical trial with 45 subjects assessed the effects of nattokinase on blood clotting factors. Subjects ingested nattokinase daily for 2 months, resulting in significant reductions in plasma levels of fibrinogen, factor VII, and factor VIII, suggesting potential cardiovascular benefits.